Dopamine, sleep, and neuronal excitability modulate amyloid-β-mediated forgetting in Drosophila

Jenifer C. Kaldun1*, Shahnaz R. Lone1,2*, Ana M. Humbert Camps1, Cornelia Fritsch1, Yves F. Widmer1, Jens V. Stein3, Seth M. Tomchik4, Simon G. Sprecher1*

1 Department of Biology, University of Fribourg, Fribourg, Switzerland, 2 Department of Animal Sciences, Central University of Punjab, Bathinda, India, 3 Department of Medicine, University of Fribourg, Fribourg, Switzerland, 4 Department of Neuroscience, The Scripps Research Institute, Jupiter, Florida, United States of America

* These authors contributed equally to this work.

simon.sprecher@unifr.ch

Abstract

Alzheimer disease (AD) is one of the main causes of age-related dementia and neurodegeneration. However, the onset of the disease and the mechanisms causing cognitive defects are not well understood. Aggregation of amyloidogenic peptides is a pathological hallmark of AD and is assumed to be a central component of the molecular disease pathways. Pan-neuronal expression of Aβ42Arctic peptides in Drosophila melanogaster results in learning and memory defects. Surprisingly, targeted expression to the mushroom bodies, a center for olfactory memories in the fly brain, does not interfere with learning but accelerates forgetting. We show here that reducing neuronal excitability either by feeding Levetiracetam or silencing of neurons in the involved circuitry ameliorates the phenotype. Furthermore, inhibition of the Rac-regulated forgetting pathway could rescue the Aβ42Arctic-mediated accelerated forgetting phenotype. Similar effects are achieved by increasing sleep, a critical regulator of neuronal homeostasis. Our results provide a functional framework connecting forgetting signaling and sleep, which are critical for regulating neuronal excitability and homeostasis and are therefore a promising mechanism to modulate forgetting caused by toxic Aβ peptides.

Introduction

Alzheimer disease (AD) is an age-related neurodegenerative disease and the most common cause of dementia in elderly people [1–3]. The prevalence of the disease is predicted to rise within the next decades, making a huge impact on healthcare systems and individuals [3,4]. Characteristic symptoms are a progressive decline in cognitive functions, gradual memory loss, and impairment of locomotor functions [1–4]. Moreover, changes in sleeping patterns and neuronal firing are widely observed among patients [3,5,6]. Hallmarks of AD include the
decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

**Abbreviations:** AD, Alzheimer disease; APP, amyloid beta precursor protein; ARM, anesthesia-resistant memory; ASM, anesthesia-sensitive memory; DAN, dopaminergic neuron; HT, high temperature; LEV, Levetiracetam; LTM, long-term memory; MB, mushroom body; MCH, 4-methylcyclohexanol; MCI, mild cognitive impairment; MTM, Middle-term memory; NFT, neurofibrillary tangle; REST, repressor element 1-silencing transcription factor; RT, room temperature; STM, Short-term memory; 3-Oct, 3-Octanol.

intercellular accumulation of β-amyloid (Aβ) plaques, intracellular neurofibrillary tangles (NFTs) made of abnormal Tau protein, and loss of neurons [7,8]. It is believed that the initiation of AD happens years before the first symptoms are evident [9,10]. In this preclinical AD phase, the brain might be able to compensate for the neuronal changes upon Aβ accumulation, therefore limiting behavioral and cognitive symptoms. However, the early steps of the disease and the role of Tau and Aβ are not well understood [11]. Hereditary, early-onset cases of AD carry mutations in the cleavage process of the amyloid beta precursor protein (APP). APP is a transmembrane protein that seems to play a role in synaptic regulations and neuronal survival. It is cleaved by 3 secretases (α-, β-, and γ-secretase) into various intra- and extracellular fragments [12,13]. Sequential cleavage by β- and γ-secretase produces the 42 amino acids long Aβ42, a peptide with high aggregation potential and the main compound of the Aβ plaques [2,3,8,14,15]. However, it remains elusive how Aβ42 aggregation causes neuronal dysfunction [14,16,17].

Increasing the Aβ42 amount by distinct methods in animal models recaptures AD phenotypes [18]. This further highlights the role of Aβ42 in the disease and suggests that animal models can be used to better understand the basic mechanisms of AD.

The fruit fly *Drosophila melanogaster* is a widely used model organism for neurobiological diseases including AD, offering versatile genetic tools [19]. Several models have been developed to assess the molecular and genetic aspects of AD [20–25]. Pan-neuronal expression of amyloidogenic Aβ42 peptides in the fly causes progressive locomotor deficits, reduced life span, and progressive learning defects [23,24,26–28].

The Arctic variant (E22G) Aβ42 peptide (Aβ<sub>Arctic</sub>), occurring in familial AD cases, is more prone to aggregation than wild-type Aβ42 and thus has a faster and more severe phenotype [16,28]. In the current study, we first showed that the expression of Aβ<sub>Arctic</sub> using pan-neuronal drivers, causes defects in 0-h and 2-h memory. However, restricted expression of Aβ<sub>Arctic</sub> to the mushroom bodies (MBs), a brain center involved in olfactory learning, did not alter 0-h memory but caused a reduction of memory performance at 2 h and later time points. This accelerated forgetting of 2-h memory was restored by using the anticonvulsant drug Levetiracetam (LEV) or by silencing the MB neurons expressing Aβ<sub>Arctic</sub>. Further, by temporally silencing neurons of the forgetting circuitry in flies expressing Aβ<sub>Arctic</sub> in the MB, we were able to rescue memory defects. A similar rescue was obtained by blocking the forgetting pathway. Moreover, inducing sleep by artificial means (either by pharmacological or by genetic manipulations) restored memory defects. Thus, our results provide experimental evidence that signals caused by toxic Aβ peptides, which are responsible for memory decay, are linked to the forgetting circuitry by yet unknown mechanisms. These observations point to a more general mechanism linking Aβ to forgetting, sleep, and neuronal excitability.

**Results**

**Restricted amyloid β expression accelerates short-term memory forgetting**

The pan-neuronal expression of Aβ42 peptides in the nervous system of *D. melanogaster* causes AD phenotypes and symptoms like those observed in other animal models and patients. Among them are neurodegeneration, the formation of plaque-like accumulations, a reduced life span, impaired locomotor ability, disruptions in sleep, and in circadian rhythms. Pan-neuronal expression of Aβ42 peptides is also reported to interfere with the ability of the fly to learn and form memories [26–28]. Before testing memory, we first tested if the *UAS-Δβ42Arctic*; *nSyb-Gal4 (nSyb>Δβ42Arctic)* flies are capable of sensing the used stimuli. The response to both odors—4-methyl-cyclohexanol (MCH) and 3-Octanol (3-Oct)—is comparable to the parental control lines (S1A and S1B Fig). Furthermore, the response to electric shock is similar to the
controls (S1C Fig). In aversive olfactory conditioning, using electric shocks as reinforcement, we observed that 7- to 9-day-old nSyb>Aβ_{42}^{Arctic} flies showed a reduced short-term memory (STM) performance compared to parental controls (Fig 1A). In agreement with previous studies [26,28], we observed that the pan-neuronal expression of UAS-Aβ_{42}^{Arctic} with nSyb-Gal4 causes reduced locomotion/mobility and reduced viability (S1D Fig). Therefore, to avoid a negative impact by reduced mobility, we did the same experiment with 4- to 5-day-old flies. Similar to the older flies, these nSyb>Aβ_{42}^{Arctic} flies also showed a significant learning defect (Fig 1B). Therefore, we decided to use younger nSyb>Aβ_{42}^{Arctic} flies to circumvent problems with reduced mobility. Furthermore, 2 h after conditioning, nSyb>Aβ_{42}^{Arctic} flies performed worse than control lines (S1D Fig). As nSyb>Aβ_{42}^{Arctic} flies have normal responses to the used odors as well as to electric shock, Aβ seems to interfere with learning itself rather than with stimulus detection. Our observations fit with previous reports suggesting that pan-neuronal Aβ expression shows STM deficits [26–28].

To test for spatially restricted deficits caused by amyloidogenic Aβ peptides, we expressed Aβ_{42}^{Arctic} specifically in the MB, the main center for learning and storing of olfactory memories [29–31]. We verified the expression using an Aβ_{42}^{Arctic}-specific monoclonal antibody and a recently published protocol [32]. Compared to the wt line, the Ok107>Aβ_{42}^{Arctic} brains show a clear signal around the area of the MB (S7A and S7B Fig). Flies expressing Aβ_{42}^{Arctic} restricted to the MB using OK107-Gal4 (OK107>Aβ_{42}^{Arctic}) showed normal scores in the sensory tests at age 7 to 9 days speaking against interference with stimuli detection (S1E–S1G Fig). Astonishingly, we found that 7- to 9-day-old OK107>Aβ_{42}^{Arctic} flies showed a normal learning performance immediately after training. The performance index was not significantly different from the parental control strains (Fig 1C). However, when testing memory performance 2 h after training, we found that OK107>Aβ_{42}^{Arctic} flies showed a lower performance compared to the controls (Fig 1D). As the performance index of OK107>Aβ_{42}^{Arctic} is not significantly different from the controls at 0 h, we assume that flies expressing Aβ_{42}^{Arctic} in the MB can learn normally but have a faster forgetting rate. However, we cannot exclude that those flies have an impaired memory consolidation. A recent study in a mouse AD model observed a forgetting phenotype without a learning defect in young mice and termed it accelerated forgetting [33]. Thus, we will use accelerated forgetting to describe our phenotype. We also observe this accelerated forgetting 4 and 6 h after training (S1H Fig shows the memory retention at 0 h, 2 h, 4 h, and 6 h after aversive training). Expression of the nontoxic Aβ_{40} variant in the MB does not affect learning at either 0 h or 2 h after training (Fig 1E and 1F), indicating that the observed effect is based on Aβ_{42}^{Arctic} itself.

Two components of aversive memory can be distinguished in *Drosophila*, anesthesia-sensitive memory (ASM) and anesthesia-resistant memory (ARM) [34]. To examine if ARM is affected by expressing Aβ_{42}^{Arctic} in the MB, flies were subjected to a cold shock after conditioning that eliminates the labile ASM component and the 2 h memory was tested. The reduced 2-h memory performance of Aβ_{42}^{Arctic} expressing flies in the MB was further decreased by cold shock treatment, indicating that also ARM components might have a higher forgetting rate (S1I Fig).

In order to exclude developmental defects, we restricted Gal4 activity to the adult stage using the GeneSwitch GAL4 system, which allows the activation of a chimeric GAL4 protein by feeding flies the steroid Mifepristone (RU486) [35]. Adult flies were aged for 7 days on food containing 250 μM RU486 or only solvent. Adult-specific pan-neuronal expression of Aβ_{42}^{Arctic} using an elav-Gal4^{GS} driver did not alter sensory perception (S2A–S2C Fig). Surprisingly, immediate memory after aversive olfactory conditioning was comparable to parental control lines (S2D Fig). However, we observed accelerated forgetting 2 h after training when compared to animals that did not receive RU486 (Fig 1G). Similar results were also obtained with an adult-specific expression of Aβ_{42}^{Arctic} restricted to the MB using an MB-Gal4^{GS} driver at both 0
Fig 1. Expression of amyloid β peptides in the brain or MBs leads to memory defects in aversive and appetitive conditioning. (A-H) Aversive olfactory conditioning experiments were conducted with Aβ42<sup>Arctic</sup> expressing flies. (A, B) Pan-neuronal expression of Aβ42<sup>Arctic</sup> impaired memory measured immediately (0 h) after training in 7- to 9-day-old flies (A) 4- to 5-day-old nSyb<sup>Gal4</sup> > Aβ42<sup>Arctic</sup> flies (B), n ≥ 12. (C, D) Flies expressing Aβ42<sup>Arctic</sup> in the MB using Ok107-Gal4 did not perform differently from parental controls for 0-h memory (C; n ≥ 12) but showed a significantly lower 2-h memory performance (D; n ≥ 12). (E, F) Flies expressing the nontoxic Aβ40 in the MB have no significant memory impairment 0 h (E) or 2 h (F) after conditioning (n ≥ 12). (G, H) The GeneSwitch Gal4 system was used to restrict the expression of Aβ42<sup>Arctic</sup> to the adult stage, by feeding flies RU486 after the hatching for 8 days until the conditioning experiments. (G) elav<sup>-Gal4</sup> GS; Aβ42<sup>Arctic</sup> flies fed with RU486 showed a lower performance index than vehicle-treated flies 2 h after training (n ≥ 12). (H) Induction of Aβ42<sup>Arctic</sup> expression after hatching in MB cells using MB-Gal4<sup>Gal4</sup> resulted in a slightly reduced 2-h memory performance (n ≥ 12). (I-N) Appetitive olfactory conditioning experiments were performed with flies expressing Aβ42<sup>Arctic</sup> in the brain or specifically in the MB. (I, J) Expression of Aβ42<sup>Arctic</sup> in the whole brain impaired memory measured immediately (I; n ≥ 12) and 24 h after conditioning (J;
n ≥ 12). (K-N) MB-specific expression of Aβ42Arctic using OK107-Gal4 did not affect 0-h memory (K), whereas 2-h (L), 6-h (M), and 24-h (N) memory performances were reduced in AD flies compared to parental control flies (n ≥ 12). See S1–S3 Figs for sensory controls and S1 Table for the data. Bar graphs represent the mean, and error bars represent the standard error of the mean. Asterisks denote significant difference between groups (∗p < 0.05, **p < 0.005, ***p < 0.001). AD, Alzheimer disease; MB, mushroom body.

https://doi.org/10.1371/journal.pbio.3001412.g001

h (S2E Fig) and 2 h (Fig 1H) after training. However, the phenotype was much milder, arguing again for an effect of amount or duration Aβ42Arctic accumulation.

Given that Aβ42Arctic accumulation seems to correlate with severity of memory impairment, we tested younger (4 to 5 days) and older (14 to 15 days) OK107>Aβ42Arctic flies. Younger OK107>Aβ42Arctic flies showed normal performance scores 2 h after aversive training (S2F Fig). It seems to require a few days of Aβ42Arctic-expression to obtain accelerated forgetting. In contrast, older OK107>Aβ42Arctic flies showed a memory impairment directly after training (S2G Fig).

In summary, we observe that temporally and spatially restricted Aβ42Arctic expression results in accelerated forgetting. This could be due to impaired consolidation or a more active forgetting pathway. Moreover, the observation that adult-specific pan-neuronal expression of Aβ42Arctic does not cause learning defects suggests that reduced associative memory might be due to developmental defects caused by Aβ42Arctic expression. Another explanation would be higher amounts of Aβ peptides accumulating in more brain areas. Nevertheless, the learning defects could also be caused by neurons included in the nSyb-Gal4 driver line but not in the OK107-Gal4 line. These findings suggest that the restricted expression of Aβ peptides might resemble earlier stages of AD.

Long-term memory is affected by the expression of Aβ42Arctic

We were interested to test if Aβ42Arctic is also affecting reward learning and long-term memory (LTM), by using sucrose as a reward in an olfactory conditioning paradigm. A single trial of appetitive olfactory conditioning is sufficient to induce LTMs [36,37]. Flies expressing Aβ42Arctic pan-neuronally using nSyb-Gal4 or restricted to the MB with OK107-Gal4 showed normal sugar response (S3A and S3B Fig). Like for aversive STM, 4- to 5-day-old nSyb>Aβ42Arctic flies showed a reduced memory performance after appetitive training (Fig 1I). This further confirms that unrestricted Aβ42Arctic expression throughout development or in more neuronal cells does interfere with memory acquisition. Because appetitive LTM forms in parallel with appetitive STM [38], we wanted to test if both memory phases are affected. nSyb-Aβ42Arctic expressing flies also displayed a drastically impaired LTM performance, which was evaluated by testing the flies 24 h after conditioning (Fig 1J). Thus, both memory phases are affected by Aβ42Arctic. We next assessed if accelerated forgetting by the targeted expression of Aβ42Arctic to the MB also affects reward middle term memory (MTM) and LTM. The flies were tested 0 h, 2 h, 6 h, or 24 h after training. Comparable to aversive training, we found that OK107>Aβ42Arctic flies do not show differences in learning compared to parental control strains when tested immediately after training (Fig 1K). At 2 h after training, the OK107>Aβ42Arctic flies seem to have a lower memory score than the control flies; however, the difference is not statistically significant. But at 6 h, and 24 h after training, OK107>Aβ42Arctic flies showed accelerated forgetting (Fig 1L-1N). Thus, spatially restricted expression of Aβ42Arctic to the MB does not interfere with the capability of the fly to form memories but results in more rapid memory decay and forgetting.

Restricted Aβ expression to dopaminergic neurons

Previous studies [26–28], as well as this study, show that pan-neuronal expression of Aβ causes learning defects. As the expression of Aβ in the MB, the main learning center does not affect
learning, these defects could be due to other neurons in the nSyb driver line required for learning. One candidate would be the dopaminergic neurons (DANs), which have a well-established role in learning [39,40]. Therefore, we expressed $A\beta_{42}^{Arctic}$ in the DANs using the TH-Gal4 driver comprising most of the DANs [41,42]. The 0-h aversive memory of those TH-$A\beta_{42}^{Arctic}$ flies was significantly reduced compared to the parental lines (S4A Fig). The PAM DANs required for reward learning are not well covered in the TH-Gal4 line [39,43], so we used GMR58E02-Gal4 (PAM-Gal4). Appetitive memory tested directly after training is significantly lower in PAM-$A\beta_{42}^{Arctic}$ flies compared to the parental controls (S4B Fig).

All in all, expression of $A\beta_{42}^{Arctic}$ in DANs seems to interfere with learning. Compared with nSyb-$A\beta_{42}^{Arctic}$ flies of the same age, the learning defect seems less severe.

### Altering neuronal excitability decreases Aβ-mediated forgetting

Brain imaging studies in AD patients show that neurons are hypoexcitable. However, patients with mild cognitive impairment (MCI), a pre-stage of AD, show hyperexcitability [2,6,44]. Therefore, the excitability of neurons seems to play a role in the disease progression with hyperexcitability occurring in early stages and hypoexcitability in later stages. Given that restricting the expression of $A\beta_{42}^{Arctic}$ to the MB might represent an early stage of AD, we hypothesized that increased neuronal activity could lead to accelerated forgetting. Moreover, a recent study showed that flies expressing $A\beta_{42}^{Arctic}$ in the MB have an enhanced firing rate when monitoring individual neurons in an ex vivo preparation [45], indicating a similar mechanism in the fly. Previous studies in mammals and flies have shown that the anticonvulsant drug LEV improves Aβ-mediated phenotypes [46–51]. LEV could rescue the neuronal firing frequency in rodent and human MCI patients [46–49,51] In addition, in flies, it also seems to prolong the shortened life span of pan-neuronal Aβ expression. Moreover, the flies had a decreased firing rate [50]. Furthermore, LEV has been shown to improve learning and memory in rodent AD models [46–51]. Therefore, we assessed if LEV administration may also influence Aβ-mediated forgetting by feeding flies for 7 days with 5 mg/kg LEV and then testing their behavior. This concentration was previously used in a Drosophila AD model and showed a reduced spontaneous firing rate [50]. Pan-neuronal expression of $A\beta_{42}^{Arctic}$ decreases the learning performance directly after training. This learning defect could not be rescued by LEV feeding, as no difference in 0-h memory performance was observed between animals that were fed with LEV and animals that were fed with control food (Fig 2A). Furthermore, 2 h after training, there seems to be no rescue (S5A Fig). Thus, LEV cannot ameliorate the defects caused by developmentally expressed $A\beta_{42}^{Arctic}$, at least in our tested conditions.

Next, we asked whether administration of LEV can rescue the accelerated forgetting defect in flies where $A\beta_{42}^{Arctic}$ peptides are specifically targeted to the MB. We found that feeding 5 mg/kg LEV to OK107>$A\beta_{42}^{Arctic}$ did not affect memory formation (Fig 2B), but significantly improved the 2-h memory of AD flies, resulting in a performance index comparable to parental control lines (Fig 2C). These experiments indicate that LEV feeding could overcome the $A\beta_{42}^{Arctic}$-mediated forgetting, maybe by decreasing neuronal excitability. However, the effects of LEV on organisms are not well resolved, and the drug might have broad effects on brain functions. An important player in regulating neuronal homeostasis is sleep. To rule out that the observed effect is due to altered sleep, we monitored the sleep of flies fed with different concentrations of LEV, (1, 2, 3, 4, and 5 mg/kg) (S5B Fig). We did not find a major effect of LEV on sleep, especially in the used concentration of 5 mg/kg. Feeding LEV does not seem to change the expression of $A\beta_{42}^{Arctic}$ in the MB (S7A and S7B Fig).

Although 5 mg/kg seems to work well for us, we tested further LEV concentration and their effect on accelerated forgetting and learning. First, we tested if a lower concentration, 2.5 mg/
kg, is able to rescue the 2-h memory of OK107＞Aβ_{42}^{Arctic} flies. Albeit the 2.5 mg/kg–fed OK107＞Aβ_{42}^{Arctic} flies have a slightly higher performance score than the vehicle fed ones, the improvement is not significant (Fig 2D). We also tested 7.5 mg/kg as a higher concentration.

Fig 2. Reducing neuronal excitability with LEV or dORKΔC rescues memory defects caused by the expression of Aβ_{42}^{Arctic}. (A) Pan-neuronal expression of Aβ_{42}^{Arctic} reduced aversive 0-h memory, which could not be restored with LEV treatment (n ≥ 12). (B) LEV treatment does not affect flies expressing Aβ_{42}^{Arctic} in the MB directly after training (n ≥ 12) but (C) restored the impaired 2-h memory performance in flies expressing Aβ_{42}^{Arctic} in the MB (n ≥ 12). (D) Flies were fed with either 2.5 or 7.5 mg/kg LEV, and 2-h aversive memory was tested. The data for 5 mg/kg are from Fig 3C (n ≥ 12). Other LEV concentrations do not seem to improve the memory performance. (E) Flies were fed with either 7.5 or 10 mg/kg LEV, and 0-h aversive memory was tested. The data for 5 mg/kg are from Fig 3B (n ≥ 12). Higher LEV concentrations seem to have a negative effect on the flies’ ability to learn (F) Expression of the nonconducting K⁺-channel dORKΔNC or constitutive conducting dORKΔC in the MB of Aβ_{42}^{Arctic}-expressing flies. At 2 h after training, dORKΔC is able to partially restore the learning performance compared to dORKΔNC (n ≥ 12). See S4 Fig for the further data on LEV and dORK and S1 Table for the data. All other details are similar to Fig 1. LEV, Levetiracetam; MB, mushroom body.

https://doi.org/10.1371/journal.pbio.3001412.g002
Compared to parental flies fed with 7.5 mg/kg, LEV-fed OK107-Aβ42Arctic flies did not perform significantly differently. However, compared to vehicle-fed flies, the memory performance was not significantly different (Fig 2D). We presumed that this concentration might have side effects and tested the learning capability of the flies. In comparison to vehicle-fed flies, the 7.5-mg/kg flies have a slight learning defect independent of genotype. We further tested 10 mg/kg and saw a severe learning defect in all tested genotypes (Fig 2E). We thus conclude that LEV works doses dependent on the flies and our model. Too low concentrations are not sufficient to rescue the accelerated forgetting phenotype, whereas too high concentrations are detrimental. However, adapting the feeding duration, for example, feeding the lower concentration for more days, could provide the desired effect. Aβ42Arctic in the MB might change the excitability of the MB intrinsic neurons causing a higher forgetting rate. To address this, we expressed dORK, a rectifying K⁺-Channel, to silence the MB neurons. The truncated dORKΔC2-construct is constantly open, whereas the dORKΔNC2-construct is not conducting [52]. Previous, dORKΔC2 has been shown to reduce the neuronal firing but does not completely silence the neurons. The dORKΔNC construct does not affect neuronal firing [52]. Therefore, only the dORKΔC2 construct should affect our phenotype. At 0 h after training, both dORKΔC2- and dORKΔNC-expressing flies showed normal learning scores (S5C Fig). As expected, expressing the dORK constructs alone in the MB did not affect learning per se (S5D Fig). At 2 h after training, flies expressing the nonconducting dORKΔNC showed AβArctic-mediated accelerated forgetting (Fig 2F). In contrast, the dORKΔC2 flies showed improved memory scores 2 h after training. At this time point, the performance of the constructs alone is not too different from normal learning scores (S5E Fig).

Taken together, it seems that silencing the MB neurons can rescue the accelerated forgetting mediated by Aβ42Arctic. This implies that the Aβ42Arctic peptide in flies could be influencing neuronal activity and therefore appears to act in a similar fashion as in mammals.

Silencing dopaminergic forgetting neurons restores Aβ-mediated forgetting

Previous studies showed that forgetting is an active, tightly regulated biological process, which may be modulated by specific neuronal circuits. A defined set of DANs from the PPL1 cluster was shown to be critical for active forgetting and opposing memory consolidation [53–57]. Genetically silencing the MP1, MV1, and V1 DANs of the PPL1 cluster using the c150-Gal4 driver line results in reduced forgetting and thus higher memory performance [54]. Moreover, this forgetting circuitry is downstream of the MB and gets activated after learning. Ongoing oscillations from DANs are required for the consolidation of memories [58,59]. We wondered if silencing these DANs will alter the accelerated forgetting in flies expressing Aβ42Arctic in the MB. To test this, we genetically silenced MP1, MV1, and V1 DANs by expressing a temperature-sensitive, dominant-negative form of Dynamin (shibirets) using the c150 Gal4 driver [60], while expressing Aβ42Arctic using the MB-specific MB247-LexA driver, thus combining the Gal4 and LexA binary expression systems. The expression of shibirets is further restricted by MBGal80ts, a temperature-sensitive repressor of Gal4 [61]. Thus, shibirets should not affect the MB during training. To inactivate the MB innervating DANs, we transferred flies to the restrictive temperature of shibirets (30˚C, high temperature (HT)) immediately after training for 2 h followed by 4 h at room temperature (RT) (21 to 22˚C, RT), while a control group was kept at RT posttraining (6 h at RT). All tested groups showed a similar memory performance when tested immediately after training (Fig 3A–3C). Similarly, when we compared 6-h memory of c150-Gal4; MB-Gal80 flies that were kept either at RT or HT, they showed similar performance indices (Fig 3B and 3C). As expected, MB247-LexA, LexAop- Aβ42Arctic flies showed...
accelerated forgetting, when compared to control flies, and the 6-h memory performance did not differ between the 2 temperature regimes (Fig 3B). However, animals that express \( A\beta_{42}^{Arctic} \) in the MB and shibire\textsuperscript{ts} in PPL1 DANs showed a significantly higher memory when exposed to a 2-h HT pulse compared to flies kept continuously at RT (Fig 3C). Thus, genetically silencing the MP1, MV1, and V1 DANs reduce \( A\beta_{42}^{Arctic} \)-induced forgetting. However, the suppressed forgetting might act independently of the \( A\beta_{42}^{Arctic} \)-induced changes. We hypothesize that the changed neuronal activity of MB neurons expressing \( A\beta_{42}^{Arctic} \) might influence the activity of the forgetting PPL1 DANs.

The forgetting DANs activate the dop1R2 receptor signaling and the downstream RAC pathway [54,55,57,62,63]. We, therefore, tested if impairing RAC signaling affects the
accelerated forgetting phenotype, by expressing both $\alpha \beta_{42}^{\text{Arctic}}$ and a dominant-negative allele of RAC (dRac:DN) together in the MB and test the 2-h aversive memory. We observed that flies expressing both $\alpha \beta_{42}^{\text{Arctic}}$ and dRac:DN have significantly better performance scores 2 h after conditioning than OK107 > $\alpha \beta_{42}^{\text{Arctic}}$ flies and have normal memory compared to parental control lines (Fig 3D).

**Induced sleep overcomes $\alpha \beta$-mediated forgetting**

Previous studies in *Drosophila* suggest that sleep can help to consolidate memories by acting on the forgetting circuit and thereby slowing down the forgetting rate [64]. In addition, inducing sleep in fly AD models was shown to be beneficial [65,66]. Moreover, in mammals, sleep can largely restore hyperexcitability caused by the overexpression of $\alpha \beta$ peptides [50] and restricts neuronal excitability to a tight physiological range [67]. We thus tested if sleep may be able to modulate the accelerated forgetting caused by $\alpha \beta$ peptides. To genetically induce sleep, we expressed UAS-TrpA1, a temperature-sensitive cation channel able to activate neurons [68], under the control of the 104y-Gal4 driver line, which is expressed in sleep-promoting dorsal fan-shaped body neurons [69,70]. Experimental and control groups were shifted to 29°C to activate TrpA1, directly after training until 1 h before testing. As expected, overexpression of $\alpha \beta_{42}^{\text{Arctic}}$ in MB247-LexA > LexAop- $\alpha \beta_{42}^{\text{Arctic}}$ resulted in an accelerated memory decay after 24 h but not immediately after olfactory conditioning (Fig 4A and 4B). Interestingly, when we induced sleep in AD flies, the LTM decay was restored, suggesting that sleep can improve the accelerated forgetting (Fig 4B). To further validate this finding, we used another Gal4 driver, R23E10-Gal4 [71,72], to activate the sleep neurons by expressing UAS-TrpA1. With this driver, we also saw a similar improvement in memory decay (Fig 4C and 4D).

As further validation, we fed flies different concentrations of Gaboxadol (THIP), which induces sleep as observed here and reported earlier (S6A and S6C Fig) [64–66]. It also induced sleep effectively in our Ok107 > $\alpha \beta_{42}^{\text{Arctic}}$ line (S6B Fig). We chose the concentration of 0.01 mg/ml, which was the lowest sleep-inducing concentration and is known to facilitate memory consolidation in different fly models from classical learning mutants to different AD models [64]. Flies were given THIP 1 day prior to aversive spaced training and until the memory performance was evaluated 24 h later. We found that nSyb > $\alpha \beta_{42}^{\text{Arctic}}$ or OK107 > $\alpha \beta_{42}^{\text{Arctic}}$ flies that were THIP fed showed a significantly higher memory performance after 24 h than flies that did not receive THIP (Fig 4E and 4F). Nevertheless, THIP might affect the locomotion activity of the fly rather than sleep. Previous reports show that THIP-induced sleep fulfills all criteria to be defined as sleep and does not interfere with locomotion [66]. Thus, we monitored the arousal ability of flies after sleep disruption. Therefore, we gave a light pulse at 18 ZT. In both control and THIP-fed groups, more flies were awake during the night (S6C Fig). During the daytime, the 2 groups are not significantly different (S6C Fig).

Moreover, it is described that pan-neuronal $\alpha \beta$ peptides cause sleep loss at a young age [50,73]. We observed that flies expressing $\alpha \beta$ peptides only in the MB show no obvious sleep defect at the age using for experiments (S6D Fig). However, we cannot exclude that there are subtle changes we do not see with the Trikinetics DAM system. Thus, our result suggests that sleep plays an important role in preventing memory decay caused by $\alpha \beta$ peptides.

**Discussion**

Here, we show that restricted expression of $\alpha \beta$ peptides to the MB of the fly in contrast to pan-neuronal expression does not interfere with memory acquisition. However, memory 2 h after conditioning or later was impaired. This implicates that the flies have a faster memory decay—accelerated forgetting. This phenotype can be at least partially rescued by (1) reducing
Fig 4. Artificial induction of sleep restores memory impairment in $A\beta_{42}$Arctic expressing flies. (B, D) Flies were transferred to 29°C after appetitive conditioning to induce sleep by activating dorsal fan-shaped body neurons with dTrpA1. (A, B) dTrpA1 was expressed with 104y-Gal4. (A) Performance indices of the 3 tested genotypes were not significantly different from each other immediately after conditioning ($n \geq 7$). (B) Inducing sleep for 23 h after conditioning could restore 24-h memory in flies, which express $A\beta_{42}$Arctic in the MB ($n \geq 14$). (C, D) Sleep was induced by using R23E10-Gal4. (C) Directly after conditioning, no significant difference between the tested genotypes was observed ($n \geq 12$). (D) 24 h after training, inducing sleep was able to rescue the memory defect of flies expressing $A\beta_{42}$Arctic in the MB ($n \geq 11$). (E, F) The drug Gabadoxol (THIP) was used to induce sleep in AD flies. Feeding THIP enhanced LTM tested 24 h after aversive spaced training in flies expressing $A\beta_{42}$Arctic in the brain (E; $n \geq 8$) or specifically in the MB (F; $n \geq 8$). See S5 Fig for the effect of THIP on sleep and S1 Table for the data. All other details are similar to Fig 1. AD, Alzheimer disease; LTM, long-term memory; MB, mushroom body.

https://doi.org/10.1371/journal.pbio.3001412.g004
neuronal activity by genetic or pharmacological means; (2) decreasing the Rac-mediated forgetting pathway; and (3) promoting sleep. Therefore, the results highlight the importance of neuronal homeostasis and sleep in the progression rate of AD.

**Restricted Aβ expression as an early-stage AD model**

The early stages of AD are of particular interest as the initiation and early progression of the disease are not well understood. It is believed that the disease is initiated years before symptoms are visible. Therefore, early stages are promising targets for therapeutic interventions to decelerate disease processing [2,3,74].

We propose that restricted Aβ expression to the MBs display similarities with an early stage of AD. In contrast to pan-neuronal expression, Ok107 > Aβ_{42}^Arctic or restricted Aβ_{42}^Arctic expression only in adult flies does not produce symptoms associated with late AD stages like locomotion defects or severe memory impairment. Nevertheless, we cannot rule out that other behaviors are affected in these flies. Likewise, AD patients start losing STM and recent memories early in the disease while keeping stable consolidated LTMs until later stages [2,75–77]. A recent study also showed that familial AD patients show accelerated forgetting [78,79]. Moreover, Aβ accumulation seems to begin in the hippocampus, which is like the MB involved in learning and memory and thus shares functional analogies. During disease progression, Aβ plaques and NFTs spread in a stereotypic pattern across the brain causing more severe phenotypes [51,80–82]. In our models, it seems that the symptoms increase with age, as longer aged Ok107 > Aβ_{42}^Arctic flies start to show learning impairment. But more observations and experiments are required. All in all, restricted Aβ expression can serve as an early-stage AD model.

**AD and neuronal excitability**

Mammalian models and brain imaging studies in AD patients indicate that the progression of the disease interferes with neuronal excitability and homeostasis. Patients with late-stage AD show hypoexcitability, whereas patients with MCI, a pre-stage of AD or early AD, show hyperexcitability [6,44,46,47,51,83,84]. A recent study in *Drosophila* using ex vivo live imaging [45] suggests that Aβ peptides are causing higher neuronal excitability. The anticonvulsant drug LEV is well known to reduce neuronal excitability. The drug is able to rescue AD phenotypes in rodent models and shows promising results in humans [46–49]. In our model, LEV is also able to rescue the accelerated forgetting phenotype. These results indicate that LEV has a similar effect in the fly and mammals. However, LEV might have more widespread effects on the whole body or indirect effects [85]. In addition, the fly metabolic system varies greatly from the mammalian one, so the drug might be differently metabolized. Reassuring, the accelerated forgetting phenotype is also rescued when blocking the neurons expressing Aβ_{42}^Arctic with dORK. However, the rescue is not completely back to wild-type levels. As we manipulate multiple neurons within the MB, we might silence neurons that are required to be active at this time point. However, the dORK line we are using is reported to be low expressing and is not completely silencing all the neurons [86–88] so the silencing might not be efficient enough for a complete rescue. Moreover, we cannot exclude that upon the long-term expression of these constructs, compensatory mechanisms or developmental defects occur. Nevertheless, both a pharmacological approach with LEV as well as genetically silencing the Aβ_{42}^Arctic-expressing neurons slows down the memory decay, thereby restoring memory performance. This indicates that Aβ_{42}^Arctic has similar effects in *Drosophila* as in mammals, making the fly a great model to study AD. Therefore, it will be useful to see how specific neurons change their activity upon Aβ_{42}^Arctic expression and to manipulate neurons more precisely.
An open question is how $\alpha\beta_42$ peptides could interfere with neuronal excitability. A recent study in a mouse AD model showed that $\alpha\beta_42$ peptides up-regulate Na$_v$-channels leading to neuronal hyperexcitability [89]. However, other studies suggest that alteration in the CREB signaling pathway by $\alpha\beta$ causes defects in synaptic plasticity and memory formation [90,91]. A further possibility of AD to modify neuronal excitability and plasticity is by down-regulation of repressor element 1-silencing transcription factor (REST), a transcription regulator required for reducing hyperexcitability and restoring neuronal homeostasis [92–94]. All in all, $\alpha\beta_42$ peptides have multiple putative targets in synapses to modify neuronal excitability.

AD and forgetting circuitry
Forgetting is an active process. In the fly, ongoing activity of a defined set of DANs from the PPL1 cluster after training activates Rac-cofilin signaling in downstream neurons causing forgetting [54–57,63]. Ok107>$\alpha\beta_42$Arctic flies have accelerated forgetting, and silencing these forgetting DANs improves the phenotype. Giving that these DANs are both upstream and downstream of the MB [54,58,95], the putative hyperexcitability of $\alpha\beta_42$Arctic-expressing neurons could enhance the activity of those DANs. This could lead to an overactivation of forgetting signaling. A recent study showed that Rac is elevated in AD patients, mouse models, and fly models [79]. Furthermore, they showed that inhibiting Rac rescues the AD phenotypes. In this study, we show that expressing the dominant-negative Rac allele can rescue the accelerated forgetting phenotype of restricted $\alpha\beta_42$Arctic expression. Thus, the involved mechanism seems to be quite similar in flies and mammals.

However, Rac or other components of the pathway could also be increased due to intrinsic changes in MB neurons caused by $\alpha\beta_42$Arctic. Careful monitoring of the activity of DANs and KCs as well as analyzing other pathway members—for example, the dop1R2/Damb dopamine receptor or coflin—could shed light on this. Moreover, the Rac-signaling pathway is not the only regulator of learning and forgetting. Whereas the Rac-pathway is implied in regulating ASM cdc42 is involved in ARM. Furthermore, learning activates the Raf/MAPK pathway to suppress forgetting [53,96,97]. Hence, there might be multiple possibilities of how $\alpha\beta_42$Arctic can enhance forgetting. Nevertheless, we cannot exclude that $\alpha\beta_42$Arctic in the MB interferes with memory consolidation and engram formation.

AD and sleep
Sleep disruption is a commonly observed phenotype in AD patients. Different studies showed that promoting sleep and improve sleep quality can improve disease [2,3,98–103]. In Drosophila, sleep was able to rescue the memory defects of AD flies [65,66]. In this study, sleep is also able to rescue the accelerated forgetting phenotype.

Sleep is an important regulator of brain function. It is implemented in memory consolidation and regulation of neuronal homeostasis. Neuronal homeostasis refers to changes in neuronal or synaptic properties to maintain a level of activity across the whole nervous system [104,105]. Further, sleep has been shown to be beneficial for $\alpha\beta$ clearance in mammalian AD models [100–102,106]. Therefore, AD has a bidirectional relationship with sleep. Although the MB functions in sleep regulation [107,108], young Ok107>$\alpha\beta_42$Arctic flies seem to exhibit normal sleep. We suggest that the dorsal fan-shaped body, another brain region for sleep regulation, especially sleep homeostasis [71,108,109] is compensating for the alterations in the MB sleep network. Another explanation would be that the amyloid load in the MB is not severe enough to disrupt the MB sleep circuits. However, more studies are required to understand the function of the sleep circuitry in our model and its relationship to $\alpha\beta$ peptides.
Interestingly, a study in *Drosophila* showed that sleep suppresses the activity of the DANs involved in forgetting and that THIP-induced sleep suppresses this forgetting [64]. Therefore, inducing sleep in our model might reduce the excitability of the DANs and MB circuit to rescue the observed AD phenotype.

In our experiments, the anticonvulsant drug LEV is not able to rescue the memory defect of nSyb>\(A\beta_{42}^{\text{Arctic}}\) flies, whereas enhancing sleep with THIP is. THIP-induced sleep was shown to fulfill the classical criteria for sleep. Previous work in *Drosophila* has shown that inducing sleep rescues AD in both a Presenilin-based model, a tau model, and a coexpression model of APP and BACE [65,66,110,111]. We hypothesize that the brain networks in the nSyb>\(A\beta_{42}^{\text{Arctic}}\) flies might be too disrupted to be simply rescued by lowering neuronal activity, whereas sleep could modify the network with more precise regulations. However, maybe longer feeding of LEV or an optimized dose could have a positive effect. Although THIP is used as a sleeping drug, we cannot exclude that it has other effects that contribute to the observed rescue.

Interestingly, Tau, another protein involved in AD and also other types of dementia, interferes with sleep, neuronal excitability, and homeostasis in mammalian models [100,101,112,113]. Therefore, untangling the relationship between AD, sleep, and neuronal homeostasis might be a path to finding a therapeutic approach.

**Beyond AD**

Due to its easy handling, short generation time, and available genetic tools, *Drosophila* is a widely used model organism. The fly’s neuronal system is simple enough to manipulate while allowing different kinds of behaviors. Because most human genes linked to diseases as well as basic molecular processes of the brain are conserved, the fly is used as a model for neurodegenerative diseases. Most studies of AD in flies use the pan-neuronal expression of \(A\beta_{42}\). However, our model used here has restricted \(A\beta_{42}^{\text{Arctic}}\) expression in neurons relevant for learning. Therefore, we can monitor the effect of \(A\beta_{42}^{\text{Arctic}}\) on specific neuropil and its features. Moreover, by using tools like genes switch or gal80ts, the expression could be even more controlled to study \(A\beta_{42}^{\text{Arctic}}\) accumulation. Additionally, by coexpressing other RNAi lines or genetic tools, modifying genes of the accelerated forgetting could be discovered. This could potentially help to find interaction partners of \(A\beta_{42}^{\text{Arctic}}\) in the neurons. Lastly, the model could be used to test other drugs. Nevertheless, there are also disadvantages. Firstly, our model is based on overexpression, so disease initiation is different than in humans. Further, not all features and symptoms of AD are present in the fly. Moreover, the human brain and the cognitive/behavioral functions are more complicated than in *Drosophila*. Another factor to consider is that the flies have a completely different digestive system and circulation, so drugs most likely have different kinetics, different effects/targets, and are differently metabolized.

The results shown here can also be used as a starting point to understand neuronal excitability better. Although there is ample evidence that local and global changes in excitability play a role in all steps of memory processing, there are still gaps in our knowledge. In this study, increasing the intrinsic excitability of the MB neurons seems to disrupt the consolidation of LTM and/or initiating the forgetting pathway. Silencing downstream neurons or manipulating global excitability levels via sleep seems to improve the observed phenotype.

**Material and methods**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Simon Sprecher (simon.sprecher@unifr.ch).
Experimental model and subject details

Fly husbandry.  *Drosophila melanogaster* flies were reared in plastic vials on standard cornmeal food (12 g agar, 40 g sugar, 40 g yeast, 80 g cornmeal per liter) and transferred to fresh food vials every 2 to 3 days. Flies were generally kept at 25˚C, 60% to 65% humidity, and exposed to 12-h light and 12-h darkness with light onset at 8 AM. OK107-Gal4 (106098) was obtained from the Kyoto stock center. nSyb-Gal4 (51635), UAS-shibire$^{ts1}$ (44222), UAS-dTrpA1 (26263), UAS-dOrk1$^{\Delta C2}$ (6586), UAS-dOrk1$^{\Delta NC}$ (6587), and GMR23E10-Gal4 (49032) were received from the Bloomington stock center. c150-Gal4; MB-Gal80 was obtained from Alex Keene (Florida Atlantic University) [114]. MB-Gal4$^{GS}$ (FlyBase ID: FBtp0015149), UAS- $\alpha$B42$^{Arctic}$, UAS- $\alpha$B40, 104Y-Gal4 (FlyBase ID: FBti0072312), and MB247-LexA LexAop-$\alpha$B42$^{Arctic}$ were gifted to us by Mark Wu and Andrew Lin (Johns Hopkins University, University of Sheffield). Elav-Gal4$^{GS}$ was obtained from Frank Hirth (King’s College London). Iso31 [115] was used as a wild-type strain. The experimental lines were generated by crossing the UAS and Gal4 constructs together. At the same time, the parental lines were crossed with Iso31 to have 1 copy of Gal4 or UAS like in the experimental strain. Moreover, Iso31 was always tested in parallel as a control.

Learning apparatus.  For behavior experiments, we used a memory apparatus that is based on Tully and Quinn’s design and modified it to allow conducting 4 memory experiments in parallel (CON-Elektronik, Greussenheim, Germany). Experiments were performed at 23 to 25˚C and 65% to 75% relative humidity. The training was performed in dim red light, and memory tests were done in complete darkness. The 2 odors used were 3-Oct (Sigma-Aldrich Cat# 218405-250G; CAS Number: 589-98-0) and MCH (Sigma-Aldrich Cat# 66360-250G; CAS Number 589-91-3) diluted in paraffin oil (Sigma-Aldrich Cat# 18512–2.5L; CAS Number 8012-95-1) 1:100, respectively. A volume of 260 µl of the diluted odors were presented in a plastic cup of 14 mm in diameter. A vacuum membrane pump ensured odor delivery at a flow rate of 7 l/min.

Aversive olfactory conditioning.  For aversive conditioning, groups of 50 to 100 flies with mixed sex were loaded in tubes lined with an electrifiable copper grid. Position in the machine and the sequence in which the genotypes were tested were randomized. Experiments in which more than half of the flies died, the flies did not move or there were technical problems with the machine, as well as human errors were excluded. The training was conducted in the morning. After an accommodation period of 90 s, the first odor was presented for 60 s. In parallel, 12 pulses of 100 V for 1.5 s were delivered with an interval of 3.5 s. After 30 s of flushing with fresh air, the second odor was presented for 60 s. For the subsequent group of flies, the order of the 2 odors was reversed. For measuring 0-h performance, flies were tested about 3 min after the end of the conditioning. To determine 2-h, 4-h, and 6-h memory performance, flies were transferred to food vials after conditioning and kept at 25˚C until the test.

Appetitive olfactory conditioning.  Before appetitive conditioning, groups of 50 to 100 flies with mixed sex were starved for 19 to 21 h in plastic vials containing damp cotton at the bottom. Experiments in which more than half of the flies died, the flies did not move or there were technical problems with the machine, as well as human errors were excluded. Position in the machine and the sequence in which the genotypes were tested were randomized. The training was conducted in the morning. The conditioning protocol consists of a 90-s accommodation period, 120 s of the first odor, 60 s of fresh air followed by 120 s of the second odor. During the first odor, flies are in a conditioning tube lined with filter paper that was soaked in water the day before the experiment and kept at 25˚C. For the second odor, flies are transferred to a conditioning tube lined with a filter paper that was soaked with a 1.5 M sucrose (Sigma-Aldrich, Cat# 84100-1KG; CAS Number 57-50-1) solution on the day before and left...
to dry at RT. After conditioning, flies were either directly tested for STM or put back in starvation vials until the memory test 2 h or 6 h later. For 24-h memory, flies were fed for 3 h after training before starving them again. One experiment consisted of 2 reciprocal conditionings, in which the odor paired with sucrose was reversed.

**Memory tests.** The memory test is identical for aversive and appetitive conditioning. Flies were loaded into a sliding compartment and transferred to a two-arm choice point. Animals were allowed to choose between 3-Oct and MCH. After 120 s, flies trapped in both arms were collected separately and counted. Based on these numbers, a preference index was calculated as follows:

\[
PREF = \left( \frac{N_{\text{arm1}} - N_{\text{arm2}}}{100} \right) / N_{\text{total}}
\]

the 2 preference indices were calculated from the 2 reciprocal experiments. The average of these 2 \(PREF\)s gives a memory performance index (PI).

\[
PI = \left( \frac{PREF_1 + PREF_2}{2} \right)
\]

**Cold shock experiments.** After conditioning, flies were transferred into precooled plastic vials that were then placed in ice water for 2 min. Afterward, flies were moved to food vials and kept at 25˚C until the memory test.

**Sensory accuracy tests.** Flies were tested for their ability to sense the 2 used odors 3-Oct and MCH as well as electric shock and sugar. Therefore, the flies were loaded into a sliding compartment and brought to a two-arm choice point. The flies were allowed to freely choose between an arm containing the stimulus and a neutral arm. All experiments were carried out in the dark. Afterward, the flies in each arm were counted, and a preference index was calculated.

For testing the odor response, the flies could choose between one of the odors in the same concentration as used for the behavior experiment and the same amount of paraffin oil for 120 s.

Preference index \(PI = \left( \frac{N_{\text{air}} - N_{\text{odor}}}{100} \right) / N_{\text{total}}\).

For shock response, the flies could freely choose between a cooper grid–lined tube getting pulses of 100 V for 60 s or a cooper grid–lined tube getting no electric shock. Preference index \(PI = \left( \frac{N_{\text{no shock}} - N_{\text{shock}}}{100} \right) / N_{\text{total}}\).

For testing sugar sensitivity, a group of flies was starved for 1 to 21 h in a tube with damp cotton on the bottom. They could choose for 120 s between a tube lined with filter paper that was soaked in 1.5 M sucrose solution the day before or a tube lined with filter paper that was soaked in distilled water the day before. Preference index \(PI = \left( \frac{N_{\text{sucrose}} - N_{\text{water}}}{100} \right) / N_{\text{total}}\).

**GeneSwitch Gal4 system.** Mifepristone (Ru486) (Sigma-Aldrich, Cat# M8046-100MG; CAS Number 84371-65-3) was dissolved in 100% EtOH and added to a total concentration of 250 μM to the fly food. Flies were fed RU486 food for 7 days before conditioning. The control group received food, in which only the vehicle (EtOH) was added for 7 days.

**Modulation of neuronal activity.** Temporal neuronal silencing was carried out by the expression of \(shibire^{ts}\), which blocks neurotransmission at the restrictive temperature of 30˚C, while at the permissive temperature of 21 to 22˚C, neurons remain unaffected [60]. For neuronal silencing experiments, flies were moved immediately after training to 30˚C for 2 h, followed by 4 h at 21 to 22˚C. For control experiments, flies were kept at 21 to 22˚C for 6 h.

\(UAS-dTrpA1\) was used to activate specific neurons. Temperature above 25˚C induces stimulation of neurons ectopically expressing \(dTrpA1\) [68]. For experiments with \(UAS-dTrpA1\), flies were raised at 23˚C. Flies were transferred to HT (29˚C) after training and were returned to 23˚C 1 h before testing. For 24-h memory, flies were exposed to 29˚C for 23 h and then transferred to 23˚C 1 h before the test.

\(UAS-dOrk1\Delta C\) was used to silence neurons, whereas \(UAS-dOrk1\Delta NC\) was used as a control.

**Drug administration.** LEV (Sigma-Aldrich, Cat# L8668-50MG; CAS Number: 102767-28-2) was added to the fly food at a concentration of 5 mg/kg, as described by Tabuchi and
colleagues [50]. Further concentrations tested were (1, 2, 3, 4 mg/kg). \( nSyb > A\beta_{42}^{Arctic} \) and the corresponding parental controls were collected 1 day after hatching and maintained on food containing LEV for 3 to 4 days. For experiments with the driver OK107-Gal4, 1-day-old flies were transferred into food vials with LEV and maintained on this food for 7 days. At the end of the LEV-feeding period, olfactory conditioning experiments were performed. After the training, flies were put back on food with LEV until the test.

Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol (THIP) (Sigma-Aldrich, Cat# T101-100MG; CAS Number 85118-33-8), was added to the food to reach concentrations of 0.01, 0.06, or 0.33 mg/ml. For conditioning experiments, the concentration of 0.01 mg/ml was used, and flies were placed on THIP food 1 day prior to conditioning and continued to be on THIP food until the test. For sleep recording experiments, the locomotor tubes contained food with different concentrations of THIP.

**Sleep experiments.** Four-day-old male flies were loaded in 5 × 65 mm plastic tubes containing food on one side. Flies were recorded using the Drosophila Activity Monitoring System (www.trikinetics.com) in an incubator at 25˚C with a 12-h light–12-h darkness cycle. Sleep was defined as 5 min of continuous rest, and the sleep data were analyzed using pySolo software [116].

**Whole-mount \( A\beta_{42} \) immunostaining.** For dissections and whole-mount \( A\beta_{42} \) immunostaining, the STAR protocol by Sekiya and Iijima was followed with minor modifications [32]. In brief, adult flies were anesthetized on ice, and the brains were dissected in cold 1X PBS (Bio-Froxx 1346LT050). After a maximum of 30 min, they were fixed for 1 h at RT in 4% paraformaldehyde in PBS and then washed with 1X PBS containing 0.5% Triton X-100 (Carl Roth 3051.3) (0.5% PBST). The permeabilized brains were treated with 10% formic acid (Sigma-Aldrich F0507-100ML) for 1 h, and then blocked (10% NGS, 1% Triton X-100, 1X PBS) before adding the primary mouse anti-\( A\beta \) 6E10 (BioLegend Cat # 803001), 1:200) and incubating overnight at 4˚C in the dark. The secondary antibody, goat Alexa Fluor 488-conjugated antimouse IgG (1:500) (Molecular Probes A11029), was also added overnight. The brains were mounted using self-made mounting media (90% Glycerol (Fischer Scientific Catalog No. BP229-1), 0.5% N-propyl gallate (Sigma P3130), 20 mM Tris (Fischer Scientific, Catalog No. BP152-5), pH 8.0) (Adapted from NIC Harvard Medical School).

The brains were imaged using a confocal microscope (Leica STELLARIS 8 FALCON) at 63X magnification with the HC PL APO CS2 63x/1.30 GLYC objective, and all were taken using the same parameters. Images were analyzed using Fiji [117], where a Z-project of 75 slices at maximum intensity was taken for each image. Then, 3 identical ROIs were measured (one for each MB and one for the background). In Microsoft Excel, the background intensity was subtracted from the MB measurements, and then they were averaged (2 measurement per image, 2 to 4 images per condition), and the SEM was calculated. The average intensity for each condition was then plotted in R using ggplot2.

**Statistical analysis**

To compare performance indices or sleep between different groups, we used one-way analysis of variance (ANOVA) with post hoc Tukey honestly significant difference (HSD) test calculator for comparing multiple treatments in R with the package multcomp. In the case of 2 groups, we performed a \( t \) test for comparison. Data are available in S1 Table.

**Supporting information**

S1 Fig. Sensory accuracy test of \( A\beta_{42}^{Arctic} \)-expressing flies. Related to Fig 1. (A–C) Sensory tests of flies expressing \( A\beta_{42}^{Arctic} \) pan-neuronally alongside the parental controls. (A) Odor
avoidance test of MCH. (B) Odor avoidance test for 3-Oct. (C) Shock response test. (D) 2-h aversive memory of nSyb > Aβ42Arctic flies is significantly different to parental controls. (E-G) Sensory test of flies expressing Aβ42Arctic in the MB alongside the parental controls. (E) Odor avoidance test of MCH. (F) Odor avoidance test for 3-Oct. (G) Shock response test. (H) Memory assessment of flies expressing AβArctic in the MB at different time points (0, 2, 4, and 6 h) after conditioning. The values for 0 h and 2 h are the same as in Fig 1C and 1D. (I) Flies were subjected to 2 min of cold shock treatment that erases the labile ASM component. Animals expressing Aβ42Arctic in the MB showed impaired 2-h memory after cold shock conditions (n ≥ 12). ASM, anesthesia-sensitive memory; MB, mushroom body; MCH, 4-methyl-cyclohexanol; 3-Oct, 3-Octanol.

S2 Fig. Sensory accuracy test of Aβ42Arctic-expressing flies using the GeneSwitch system. Related to Fig 1. (A-C) Sensory tests of flies expressing Aβ42Arctic restricted to the adult stage with ElavGS alongside the parental controls. Flies were fed with either RU486 or the vehicle. (A) Odor avoidance test of MCH. (B) Odor avoidance test for 3-Oct. (C) Shock response test memory scores of the tested genotypes did not differ from each other. (D) 0-h aversive memory of flies expressing Aβ42Arctic in the adult brain using the ElavGS system. Flies were fed with either RU486 or the vehicle. (E) 0-h aversive memory of flies expressing Aβ42Arctic in the adult MB using the MBGS system. Flies were fed with either RU486 or the vehicle. (F) Memory performance 2 h after aversive training of 4- to 5-day-old OK107 > Aβ42Arctic flies and parental controls with no accelerated forgetting phenotype. (G) 14- to 15-day-old OK107 > Aβ42Arctic flies show a learning defect compared to parental controls. All other details are similar to Fig 1. MB, mushroom body; MCH, 4-methyl-cyclohexanol; 3-Oct, 3-Octanol.

S3 Fig. Sugar sensing capability of Aβ42Arctic-expressing flies. Related to Fig 1. (A) Sugar response of flies expressing Aβ42Arctic pan-neuronally alongside parental control lines. (B) Sugar response of flies expressing Aβ42Arctic in the MB alongside the parental controls. All other details are similar to Fig 1. MB, mushroom body.

S4 Fig. Expression of amyloid β peptides in the DANs. Related to Fig 1. (A) Aversive olfactory conditioning experiment was conducted with Aβ42Arctic-expressing flies in most DANs. TH > Aβ42Arctic flies have a learning defect after training (n ≥ 12) (B) Appetitive olfactory conditioning with flies expressing Aβ42Arctic in the PAM cluster. PAM > Aβ42Arctic flies have a learning defect immediately after training (n ≥ 12). See S1 Table for the data. Bar graphs represent the mean, and error bars represent the standard error of the mean. Asterisks denote significant difference between groups (*p < 0.05, **p < 0.005, ***p < 0.001). DAN, dopaminergic neuron.

S5 Fig. Effect of LEV on sleep. Related to Fig 2. (A) Effect of LEV on the 2-h aversive memory of nSyb > Aβ42Arctic flies. The memory impairment is not rescued by LEV. (B) Amount of day and night time sleep of flies receiving different amounts of LEV. (C) Expression of the nonconducting K+ channel dORKΔC or constitutive conducting dORKΔC in the MB of Aβ42Arctic-expressing flies. At 0 h after training, no significant difference is observed (n ≥ 8). (D, E) Memory performance of flies only expressing the dORK constructs 0 h (D) and 2 h (E) after training. (n ≥ 8). All other details are similar to Fig 1. LEV, Levetiracetam; MB, mushroom body.
S6 Fig. Gabadoxol (THIP) feeding induces sleep. Related to Fig 4. (A) Sleep profile of wild-type Canton-S flies that received different concentrations of THIP or the vehicle. (B) Sleep profile of OK107-Aβ42Arctic flies and parental controls on THIP (C) Quantification of daytime and nighttime sleep; daytime and nighttime sleep was significantly increased in flies that received 0.01, 0.06, or 0.33 mg/ml THIP (n ≥ 24), compared to control flies that received no THIP. (D) Arousal response of THIP-fed flies. At ZT18, a light pulse was used to wake the flies up. (E) Sleep profile of 8- to 10-day-old flies expressing AβArctic in the MB. All other details are similar to Fig 1. MB, mushroom body.

(TIF)

S7 Fig. Expression of Aβ42Arctic in the brain. Related to Figs 1 and 3. (A) Whole-mount immunostaining of Iso31 and Ok107>Aβ42Arctic brains with 6E10 antibody. The top row shows untreated flies, and the bottom row brains of flies fed with 5 mg/kg LEV. (B) Quantification of Aβ42Arctic-expression. LEV, Levetiracetam.

(TIF)

S1 Table. Data and statistical analysis for preparing the figures. Related to all figures.

(XLSX)

Acknowledgments

We would like to thank H. Tanimoto, M. Wu, A. Lin, F. Hirth, D. Pauls, R. Davis, T. Preat, the Kyoto and Bloomington stock centers for fly strains. We would like to thank colleagues of the Sprecher lab for valuable input and discussions.

Author Contributions

Conceptualization: Shahnaz R. Lone, Simon G. Sprecher.

Data curation: Jenifer C. Kaldun.

Formal analysis: Jenifer C. Kaldun, Shahnaz R. Lone, Cornelia Fritsch.

Funding acquisition: Simon G. Sprecher.

Investigation: Jenifer C. Kaldun, Shahnaz R. Lone, Ana M. Humbert Camps, Yves F. Widmer, Jens V. Stein, Seth M. Tomchik.

Methodology: Jenifer C. Kaldun, Shahnaz R. Lone, Seth M. Tomchik.

Project administration: Simon G. Sprecher.

Resources: Simon G. Sprecher.

Supervision: Jens V. Stein, Simon G. Sprecher.

Validation: Jenifer C. Kaldun.

Visualization: Jenifer C. Kaldun, Shahnaz R. Lone.

Writing – original draft: Jenifer C. Kaldun, Yves F. Widmer.

Writing – review & editing: Jens V. Stein, Seth M. Tomchik, Simon G. Sprecher.

References

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011; 1(1):a006189. https://doi.org/10.1101/cshperspect.a006189 PMID: 22229116
2. Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012; 2(5):a006148. https://doi.org/10.1101/cshperspect.a006148 PMID: 22553492

3. Gaugler J, James B, Johnson T, Marin A, Weuve J. Assoc As. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 2019; 15(3):321–87.

4. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112–7. https://doi.org/10.1016/S0140-6736(05)67889-0 PMID: 16360788

5. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med. 2000; 343(7):450–6. https://doi.org/10.1056/NEJM200008173430701 PMID: 10944562

6. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer’s disease: an independent component analysis. J Neurosci. 2006; 26(40):10222–31. https://doi.org/10.1523/JNEUROSCI.2250-06.2006 PMID: 17021177

7. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011; 6(1):27. https://doi.org/10.1186/1750-1326-6-27 PMID: 21527012

8. Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003; 70(1):1–32. https://doi.org/10.1016/s0301-0082(03)00089-3 PMID: 12927332

9. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012; 11(12):1048–56. https://doi.org/10.1016/S1474-4422(12)70228-4 PMID: 23137948

10. Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J Alzheimers Dis. 2018; 64:S567–610. https://doi.org/10.3233/JAD-179941 PMID: 29843241

11. Kametani F, Hasegawa M. Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer’s Disease. Front Neurosci. 2018; 12:25. https://doi.org/10.3389/fnins.2018.00025 PMID: 29440986

12. Thnakanran G, Koo EH. Amyloid Precursor Protein Trafficking, Processing, and Function*. J Biol Chem. 2008; 283(44):29615–9. https://doi.org/10.1074/jbc.R800019200 PMID: 18650430

13. Müller UC, Deller T, Korte M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat Rev Neurosci. 2017; 18(5):281–98. https://doi.org/10.1038/nrn.2017.29 PMID: 28360418

14. Vanderheyden WM, Lim MM, Musiek ES, Gerstner JR. Alzheimer’s Disease and Sleep-Wake Disturbances: Amyloid, Astrocytes, and Animal Models. J Neurosci. 2018; 38(12):2901–10. https://doi.org/10.1523/JNEUROSCI.1135-17.2017 PMID: 29563238

15. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015; 67(2):195–203. https://doi.org/10.1016/j.pharep.2014.09.004 PMID: 25712639

16. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001; 4(9):887–93. https://doi.org/10.1038/nn0901-887 PMID: 11528419

17. Wu L, Rosa-Neto P, Hsiung GY, Sadovnick AD, Masellis M, Black SE, et al. Early-onset familial Alzheimer’s disease (EOFAD). Can J Neurol Sci. 2012; 39(4):436–45. https://doi.org/10.1017/s0317167100013949 PMID: 22728850

18. Randall AD, Witton J, Booth C, Hynes-Allen A, Brown JT. The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. Neuropharmacology. 2010; 59(4–5):243–67. https://doi.org/10.1016/j.neuropharm.2010.02.011 PMID: 20167227

19. Jeibmann A, Paulus W. Drosophila melanogaster as a model organism of brain diseases. Int J Mol Sci. 2009; 10(2):407–40. https://doi.org/10.3390/jmns10020407 PMID: 19333415

20. Fernandez-Funez P, de Mena L, Rincon-Limas DE. Modeling the complex pathology of Alzheimer’s disease in Drosophila. Exp Neurol. 2015; 274(Pt A):58–71. https://doi.org/10.1016/j.expneurol.2015.05.013 PMID: 26024860

21. Mhatre SD, Paddock BE, Saunders AJ, Marenda DR. Invertebrate models of Alzheimer’s disease. J Alzheimers Dis. 2013; 33(1):3–16. https://doi.org/10.3233/JAD-2012-121204 PMID: 22886023

22. Moloney A, Sattelle DB, Lomas DA, Crowther DC. Alzheimer’s disease: insights from Drosophila melanogaster models. Trends Biochem Sci. 2010; 35(4):228–35. https://doi.org/10.1016/j.tibs.2009.11.004 PMID: 20036556
23. Iijima K, Iijima-Ando K. Drosophil a models of Alzheimer’s amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. J Alzheimers Dis. 2008; 15(4):523–40. https://doi.org/10.3233/jad-2008-15402 PMID: 19096154

24. Iijima-Ando K, Iijima K. Transgenic Drosophil a models of Alzheimer’s disease and tauopathies. Brain Struct Funct. 2010; 214(2–3):245–62. https://doi.org/10.1007/s00429-009-0234-4 PMID: 19967412

25. Prüßing K, Voigt A, Schulz JB. Drosophil a melanogaster as a model organism for Alzheimer’s disease. Mol Neurodegener. 2013; 8:35–41. https://doi.org/10.1186/1750-1326-8-35 PMID: 24267573

26. Iijima K, Chiang HC, Hearn SA, Hakker I, Gatt A, Shenton C, et al. Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophil a. PLoS ONE. 2008; 3(2):e1703. https://doi.org/10.1371/journal.pone.0001703 PMID: 18301778

27. Iijima K, Liu HP, Chiang AS, Hearn SA, Konstolaki M, Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophil a: a potential model for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004; 101(17):6623–8. https://doi.org/10.1073/pnas.0400895101 PMID: 15069204

28. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, et al. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophil a model of Alzheimer’s disease. Neuroscience. 2005; 132 (1):123–35. https://doi.org/10.1016/j.neuroscience.2004.12.025 PMID: 15780472

29. Heisenberg M, Borst A, Wagner S, Byers D. Drosophil a mushroom body mutants are deficient in olfactory learning. J Neurogenet. 1985; 2(1):1–30. https://doi.org/10.3109/01677068509100140 PMID: 4020527

30. Keene AC, Waddell S. Drosophil a olfactory memory: single genes to complex neural circuits. Nat Rev Neurosci. 2007; 8(5):341–54. https://doi.org/10.1038/nrn2098 PMID: 17453015

31. Dubnau J, Grady L, Kitamoto T, Tully T. Disruption of neurotransmission in Drosophila mushroom body blocks retrieval but not acquisition of memory. Nature. 2001; 411(6836):476–80. https://doi.org/10.1038/35078077 PMID: 11373680

32. Sekiya M, Iijima KM. Phenotypic analysis of a transgenic Drosophil a model of Alzheimer’s amyloid-β toxicity. STAR Protoc. 2021; 2(2):100501. https://doi.org/10.1016/j.xpro.2021.100501 PMID: 33997815

33. Beglopoulos V, Tulloch J, Roe AD, Daumas S, Ferrington L, Watson R, et al. Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. Nat Commun. 2016; 7:11761. https://doi.org/10.1038/ncomms11761 PMID: 27249364

34. Quinn WG, Dudai Y. Memory phases in Drosophil a. Nature. 1976; 262(5569):576–7. https://doi.org/10.1038/262576a0 PMID: 822344

35. Nicholson L, Singh GK, Osterwalder T, Roman GW, Davis RL, Keshishian H. Spatial and temporal control of gene expression in Drosophil a using the inducible GeneSwitch GAL4 system. I. Screen for larval nervous system drivers. Genetics. 2008; 178(1):215–34. https://doi.org/10.1534/genetics.107.081968 PMID: 18202369

36. Krashes MJ, Waddell S. Rapid consolidation to a radish and protein synthesis-dependent long-term memory after single-session appetitive olfactory conditioning in Drosophil a. J Neurosci. 2008; 28 (12):3103–13. https://doi.org/10.1523/JNEUROSCI.5333-08.2008 PMID: 18354013

37. Colomb J, Kaiser L, Chabaud MA, Pretat P. Parametric and genetic analysis of Drosophil a appetitive long-term memory and sugar motivation. Genes Brain Behav. 2009; 8 (4):407–15. https://doi.org/10.1111/j.1601-183X.2009.00482.x PMID: 19220480

38. Trannoy S, Redt-Clouet C, Dura JM, Preat T. Parallel processing of appetitive short- and long-term memories in Drosophil a. Curr Biol. 2011; 21(19):1647–53. https://doi.org/10.1016/j.cub.2011.08.032 PMID: 21962716

39. Waddell S. Reinforcement signalling in Drosophil a; dopamine does it all after all.Curr Opin Neurobiol. 2013; 23(3):324–9. https://doi.org/10.1016/j.conb.2013.01.005 PMID: 23391527

40. Siju KP, De Backer JF, Grunwald Kadow IC. Dopamine modulation of sensory processing and adaptive behavior in flies. Cell Tissue Res. 2021; 383(1):207–25. https://doi.org/10.1007/s00441-020-03371-x PMID: 33515291

41. Mao Z, Davis RL. Eight different types of dopaminergic neurons innervate the Drosophila mushroom body neuropil: anatomical and physiological heterogeneity. Front Neural Circuits. 2009; 3:5. https://doi.org/10.3389/neuro.04.005.2009 PMID: 19597562

42. Ueno T, Kume K. Functional characterization of dopamine transporter in vivo using Drosophila melanogaster behavioral assays. Front Behav Neurosci. 2014; 8(303). https://doi.org/10.3389/fnbeh.2014.00303 PMID: 25232310

43. Liu C, Plaïais P-Y, Yamagata N, Pfeiffer BD, Aso Y, Friedrich AB, et al. A subset of dopamine neurons signals reward for odour memory in Drosophila. Nature. 2012; 488(7412):512–6. https://doi.org/10.1038/nature11304 PMID: 22810589
44. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005; 65(3):404–11. https://doi.org/10.1212/01.wnl.0000171450.97464.49 PMID: 16087905

45. Coelho DS, Moreno E. Neuronal Selection Based on Relative Fitness Comparison Detects and Eliminates Amyloid-β-Induced Hyperactive Neurons in Drosophila. iScience. 2020; 23(9):101468–. https://doi.org/10.1016/j.isci.2020.101468 PMID: 32866827

46. Bakker A, Albert MS, Krauss GL, Speck CL, Gallagher M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin. 2015; 7:688–98. https://doi.org/10.1016/j.nicl.2015.02.009 PMID: 25844322

47. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012; 74(3):467–74. https://doi.org/10.1016/j.neuron.2012.03.023 PMID: 22578498

48. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A. 2012; 109(42):E2895–903. https://doi.org/10.1073/pnas.112081109 PMID: 22869752

49. Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010; 35(4):1016–25. https://doi.org/10.1038/npp.2009.207 PMID: 20032967

50. Tabuchi M, Lone SR, Liu S, Liu Q, Zhang J, Spira AP, et al. Sleep interacts with abeta to modulate intrinsic neuronal excitability. Curr Biol. 2015; 25(6):702–12. https://doi.org/10.1016/j.cub.2015.01.016 PMID: 2574641

51. Zott B, Busche MA, Sperling RA, Konnerth A. What Happens with the Circuit in Alzheimer’s Disease in Mice and Humans? Annu Rev Neurosci. 2018; 41:277–97. https://doi.org/10.1146/annurev-neuro-080317-061725 PMID: 29986165

52. Nitabach MN, Blau J, Holmes TC. Electrical silencing of Drosophila pacemaker neurons stops the free-running circadian clock. Cell. 2002; 109(4):485–95. https://doi.org/10.1016/s0092-8674(02)00737-7 PMID: 12086605

53. Gao Y, Shuai Y, Zhang X, Peng Y, Wang L, He J, et al. Genetic dissection of active forgetting in labile and consolidated memories in Drosophila. Proc Natl Acad Sci U S A. 2019; 116(42):21191–7. https://doi.org/10.1073/pnas.1903763116 PMID: 31488722

54. Berry JA, Cervantes-Sandoval I, Nicholas EP, Davis RL. Dopamine is required for learning and forgetting in Drosophila. Neuron. 2012; 74(3):530–42. https://doi.org/10.1016/j.neuron.2012.04.007 PMID: 22578504

55. Berry JA, Phan A, Davis RL. Dopamine Neurons Mediate Learning and Forgetting through Bidirectional Modulation of a Memory Trace. Cell Rep. 2018; 25(3):651–62. https://doi.org/10.1016/j.celrep.2018.09.051 PMID: 30332645

56. Shuai Y, Hirokawa A, Ai Y, Zhang M, Li W, Zhong Y. Dissecting neural pathways for forgetting in Drosophila olfactory aversive memory. Proc Natl Acad Sci U S A. 2015; 112(48):E6663–72. https://doi.org/10.1073/pnas.1512792112 PMID: 26627257

57. Shuai Y, Hu Y, Qin H, Campbell RA, Zhong Y. Distinct molecular underpinnings of Drosophila olfactory trace conditioning. Proc Natl Acad Sci U S A. 2011; 108(50):20201–6. https://doi.org/10.1073/pnas.1107489109 PMID: 22129366

58. Pavlovska Y, Schor J, Placais PY, Preat T. A GABAergic Feedback Shapes Dopaminergic Input on the Drosophila Mushroom Body to Promote Appetitive Long-Term Memory. Curr Biol. 2018; 28(11):1783–93. https://doi.org/10.1016/j.cub.2018.04.040 PMID: 29779874

59. Placais PY, Tranoy S, Isabel G, Aso Y, Siwanowicz I, Belliart-Guerin G, et al. Slow oscillations in two pairs of dopaminergic neurons gate long-term memory formation in Drosophila. Nat Neurosci. 2012; 15(4):592–9. https://doi.org/10.1038/nn.3055 PMID: 22366756

60. Kitamoto T. Conditional modification of behavior in Drosophila by targeted expression of a temperature-sensitive shibire allele in defined neurons. J Neurobiol. 2001; 47(2):81–92. https://doi.org/10.1002/neu.1018 PMID: 11291999

61. McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal Rescue of Memory Dysfunction in Drosophila. Science. 2003; 302(5651):1765–8. https://doi.org/10.1126/science.1089035 PMID: 14657498

62. Berry J, Krause WC, Davis RL. Chapter 18 Olfactory memory traces in Drosophila. Essence of Memory. Prog Brain Res. 2008;293–304.
63. Shuai Y, Lu B, Hu Y, Wang L, Sun K, Zhong Y. Forgetting is regulated through Rac activity in Drosophila. Cell. 2010; 140(4):579–89. https://doi.org/10.1016/j.cell.2009.12.044 PMID: 20178749

64. Berry JA, Cervantes-Sandoval I, Chakraborty M, Davis RL. Sleep Facilitates Memory by Blocking Dopamine Neuron-Mediated Forgetting. Cell. 2015; 161(7):1656–67. https://doi.org/10.1016/j.cell.2015.05.027 PMID: 26073942

65. Dissel S, Klose M, Donlea J, Cao L, English D, Winsky-Sommerer R, et al. Enhanced sleep reverses memory deficits and underlying pathology in Drosophila models of Alzheimer’s disease. Neurobiol Sleep Circadian Rhythms 2017; 2:15–26. https://doi.org/10.1016/j.nbscr.2016.09.001 PMID: 29094110

66. Dissel S, Angadi V, Kirszenblat L, Suzuki Y, Donlea J, Klose M, et al. Sleep restores behavioral plasticity to Drosophila mutants. Curr Biol. 2015; 25(10):1270–81. https://doi.org/10.1016/j.cub.2015.03.027 PMID: 25913403

67. Watson BO, Levenstein D, Greene JP, Gelinas JN, Buzsaki G. Network Homeostasis and State Dynamics of Neocortical Sleep. Neuron. 2016; 90(4):839–52. https://doi.org/10.1016/j.neuron.2016.03.036 PMID: 27133462

68. Hamada FN, Rosenzweig M, Kang K, Pulver SR, Ghezzi A, Jegla TJ, et al. An internal thermal sensor controlling temperature preference in Drosophila. Nature. 2008; 454(7201):217–20. https://doi.org/10.1038/nature07001 PMID: 18548007

69. Donlea JM, ThimGAN MS, Suzuki Y, Gottschalk L, Shaw PJ. Inducing sleep by remote control facilitates memory consolidation in Drosophila. Science. 2011; 332(6037):1571–6. https://doi.org/10.1126/science.1202249 PMID: 26073942

70. Dag U, Lei Z, Le JQ, Wong A, Bushey D, Keleman K. Neuronal reactivation during post-learning sleep consolidates long-term memory in Drosophila. Elife. 2019; 8. https://doi.org/10.7554/eLife.42786 PMID: 30801246

71. Donlea JM, Pimentel D, Talbot CB, Kempf A, Omoto JJ, Hartenstein V, et al. Recurrent Circuitry for Balancing Sleep Need and Sleep. Neuron. 2018; 97(2):378–89. https://doi.org/10.1016/j.neuron.2017.12.016 PMID: 29307711

72. Donlea Jeffrey M, Pimentel D, Miesenböck G. Neuronal Machinery of Sleep Homeostasis in Drosophila. Neuron. 2014; 81(4):670–6. https://doi.org/10.1016/j.neuron.2013.12.013 PMID: 24559676

73. Gerstner JR, Lenz O, Vanderheyden WM, Chan MT, Pfeifferberger C, Pack AJ. Amyloid-beta induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila. J Neurosci Res. 2017; 95(8):1548–64. https://doi.org/10.1002/jnr.23778 PMID: 27320125

74. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Pralutus Alzheimers disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12(3):292–323. https://doi.org/10.1016/j.jalz.2016.02.002 PMID: 27012484

75. Gilbert JG, Levee RF. Patterns of declining memory. J Gerontol. 1971; 26(1):70–5. https://doi.org/10.1093/geronj/26.1.70 PMID: 5540322

76. Luszcz MA, Bryan J. Toward Understanding Age-Related Memory Loss in Late Adulthood. Gerontol. 1999; 45(1):2–9. https://doi.org/10.1159/000022048 PMID: 9852374

77. Crook TH, West RL. Name recall performance across the adult life-span. Br J Psychol. 1990; 81(Pt 3):335–49. https://doi.org/10.1111/j.2044-8295.1990.tb02365.x PMID: 2224395

78. Weston PSJ, Nicholas JM, Henley SMD, Liang Y, Macpherson K, Donnachie E, et al. Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 2018; 17(2):123–32. https://doi.org/10.1016/S1474-4422(17)30434-9 PMID: 29413314

79. Wu W, Du S, Shi W, Liu Y, Hu Y, Xie Z, et al. Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer’s disease. Protein Cell. 2019; 10(10):745–59. https://doi.org/10.1007/s13238-019-0641-0 PMID: 31321704

80. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002; 58(12):1791–800. https://doi.org/10.1212/wnl.58.12.1791 PMID: 12084879

81. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239–59. https://doi.org/10.1007/BF00308809 PMID: 1759558

82. Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016; 80(2):247–58. https://doi.org/10.1002/ana.24711 PMID: 27323247

83. Hämäläinen A, Pihlajamäki M, Tanila H, Hänninen T, Niskanen E, Tervo S, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging. 2007; 28(12):1889–903.
Mechanisms controlling Amyloid-beta-mediated forgetting

84. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends Neurosci. 2011; 34(8):430–42.

85. Deshpande LS, Delorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol. 2014; 5:11. https://doi.org/10.3389/fneur.2014.00011 PMID: 24550884

86. Park D, Griffith LC. Electrophysiological and Anatomical Characterization of PDF-Positive Clock Neurons in the Intact Adult Drosophila Brain. J Neurophysiol. 2006; 95(6):3955–60. https://doi.org/10.1152/jn.00117.2006 PMID: 16554503

87. Hodge J. Ion channels to inactivate neurons in Drosophila. Front Mol Neurosci. 2009; 2(13). https://doi.org/10.3389/neuro.02.013.2009 PMID: 19750193

88. Nitabach M. P(UAS-dORKdelta-C) and P(UAS-dORKdelta-NC) insertions. 2002.

89. Ciccone R, Franco C, Picciiali I, Boscia F, Casamassa A, de Rosa V, et al. Amyloid beta-Induced Upregulation of Nav1.6 Underlies Neuronal Hyperactivity in Tg2576 Alzheimer’s Disease Mouse Model. Sci Rep. 2019; 9(1):13592. https://doi.org/10.1038/s41598-019-50018-1 PMID: 31537873

90. Espana J, Valero J, Minano-Molina AJ, Masgraup R, Martin E, Guardia-Laguarta C, et al. beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J Neurosci. 2010; 30(28):9402–10. https://doi.org/10.1523/JNEUROSCI.2154-10.2010 PMID: 20631169

91. Vitolo OV, Sant, Angelo A, Costanzo V, Battaglia F, Arancio O, et al. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci. 2002; 99(20):13217. https://doi.org/10.1073/pnas.172504199 PMID: 12244210

92. Pecoraro-Bisogni F, Lignani G, Contestaible A, Castrollorio E, Pozzi D, Rocchi A, et al. REST-Dependent Presynaptic Homeostasis Induced by Chronic Neuronal Hyperactivity. Mol Neurobiol. 2018; 55(6):4959–72. https://doi.org/10.1007/s12035-017-0698-9 PMID: 28760615

93. Hwang JY, Zukin RS. REST, a master transcriptional regulator in neurodegenerative disease. Curr Opin Neurobiol. 2018; 48:193–200. https://doi.org/10.1016/j.conb.2017.12.008 PMID: 29351877

94. Lu T, Aron L, Zhuo J, Pan Y, Kim H, Chen Y, et al. REST and stress resistance in ageing and Alzheimer’s disease. Nature. 2014; 507(7493):448–54. https://doi.org/10.1038/nature13163 PMID: 24670762

95. Cognigni P, Felsenberg J, Waddell S. Do the right thing: neural network mechanisms of memory formation, expression and update in Drosophila. Curr Opin Neurobiol. 2018; 49:51–8. https://doi.org/10.1016/j.conb.2017.12.002 PMID: 29258011

96. Sun H, Nishioka T, Hiramatsu S, Kondo S, Amano M, Kaibuchi K, et al. Dopamine Receptor Dop1R2 Stabilizes Appetitive Olfactory Memory through the Raf/MAPK Pathway in Drosophila. J Neurosci. 2020; 40(14):2935–42. https://doi.org/10.1523/JNEUROSCI.1572-19.2020 PMID: 32102921

97. Zhang X, Li Q, Wang L, Liu ZJ, Zhong Y. Active Protection: Learning-Activated Raf/MAPK Activity Protects Labile Memory from Rac1-Independent Forgetting. Neuron. 2018; 98(1):142–55. https://doi.org/10.1016/j.neuron.2018.02.025 PMID: 29551489

98. Moe KE, Vitiello MV, Larsen LH, Prinz PN. Symposium: Cognitive processes and sleep disturbances: Sleep/wake patterns in Alzheimer’s disease: relationships with cognition and function. J Sleep Res. 1995; 4(1):15–20. https://doi.org/10.1111/j.1365-2669.1995.tb00145.x PMID: 10607136

99. Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to moderate Alzheimer’s disease. Sleep Med. 2005; 6(4):347–52. https://doi.org/10.1016/j.sleep.2004.12.005 PMID: 15978517

100. Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019; 363(6429):880–4. https://doi.org/10.1126/science.aav2546 PMID: 30679382

101. Holth J, Patel T, Holtzman DM. Sleep in Alzheimer’s Disease—Beyond Amyloid. Neurobiol Sleep Circadian Rhythms. 2017; 2:4–14. https://doi.org/10.1016/j.nbscr.2016.08.002 PMID: 28217760

102. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015; 47:e148. https://doi.org/10.1038/emm.2014.121 PMID: 25766617

103. Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Yu YS. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol. 2018; 75(5):582–90. https://doi.org/10.1001/jamaneurol.2017.4719 PMID: 29379963

104. Davis GW. Bezpbrzovzanny I. Maintaining the Stability of Neural Function: A Homeostatic Hypothesis. Annu Rev Physiol. 2001; 63(1):947–69. https://doi.org/10.1146/annurev.physiol.63.1.847 PMID: 11181978

105. Golowasch J. Neuronal Homeostasis: Voltage Brings It All Together. Curr Biol. 2019; 29(13):R641–R4. https://doi.org/10.1016/j.cub.2019.05.029 PMID: 31287985
106. Feld GB, Born J. Sculpting memory during sleep: concurrent consolidation and forgetting. Curr Opin Neurobiol. 2017; 44:20–7. https://doi.org/10.1016/j.conb.2017.02.012 PMID: 28278432

107. Artiushin G, Sehgal A. The Drosophila circuity of sleep-wake regulation. Curr Opin Neurobiol. 2017; 44:243–50. https://doi.org/10.1016/j.conb.2017.03.004 PMID: 28366532

108. Joiner WJ, Crocker A, White BH, Sehgal A. Sleep in Drosophila is regulated by adult mushroom bodies. Nature. 2006; 441(7094):757–60. https://doi.org/10.1038/nature04811 PMID: 16760980

109. Qian Y, Cao Y, Deng B, Yang G, Li J, Xu R, et al. Sleep homeostasis regulated by 5HT2b receptor in a small subset of neurons in the dorsal fan-shaped body of drosophila. Elife. 2017; 6:e26519. https://doi.org/10.7554/eLife.26519 PMID: 28984573

110. Dissel S, Melnattur K, Shaw PJ. Sleep, Performance, and Memory in Flies. Curr Sleep Med Rep. 2015; 1(1):47–54. https://doi.org/10.1007/s40675-014-0006-4 PMID: 26120553

111. Dissel S. Drosophila as a Model to Study the Relationship Between Sleep, Plasticity, and Memory. Front Physiol. 2020; 11:533. https://doi.org/10.3389/fphys.2020.00533 PMID: 32547415

112. Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015; 36(2):693–709. https://doi.org/10.1016/j.neurobiolaging.2014.09.007 PMID: 25442111

113. Winer JR, Mander BA, Helfrich RF, Maass A, Harrison TM, Baker SL, et al. Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain. J Neurosci. 2019; 39(32):6315–24. https://doi.org/10.1523/JNEUROSCI.0503-19.2019 PMID: 31209175

114. Dubnau J, Chiang AS, Grady L, Barditch J, Gossweiler S, McNeil J, et al. The staufen/pumilio pathway is involved in Drosophila long-term memory. Curr Biol. 2003; 13(4):286–96. https://doi.org/10.1016/S0960-9822(03)00064-2 PMID: 12593794

115. Ryder E, Blows F, Ashburner M, Bautista-Llacer R, Coulson D, Drummond J, et al. The DrosDel Collection. A Set of P-Element Insertions for Generating Custom Chromosomal Aberrations in Drosophila melanogaster. Genetics. 2004; 167(2):797–813. https://doi.org/10.1534/genetics.104.026658 PMID: 15238529

116. Gilestro GF, Cirelli C. pySolo: a complete suite for sleep analysis in Drosophila. Bioinformatics. 2009; 25(11):1466–7. https://doi.org/10.1093/bioinformatics/btp237 PMID: 19369499

117. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676–82. https://doi.org/10.1038/nmeth.2019 PMID: 22743772